Placenta-derived stem cells (PDSCs) have gained interest as an alternative source of stem cells for regenerative medicine because of their potential for self-renewal and differentiation and their immunomodulatory properties. Although many studies have characterized various PDSCs biologically, the properties of the self-renewal and differentiation potential among PDSCs have not yet been directly compared. We consider the characterization of chorionic-plate-derived mesenchymal stem cells (CP-MSCs) and Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) among various PDSCs and the assessment of their differentiation potential to be important for future studies into the applicability and effectiveness of PDSCs in cell therapy. In the present study, the capacities for self-renewal and multipotent differentiation of CP-MSCs and WJ-MSC isolated from normal term placentas were compared. CP-MSCs and WJ-MSCs expressed mRNAs for the pluripotent stem cell markers Oct-4, Nanog, and Sox-2. Additionally, HLA-G for immunomodulatory effects was found to be expressed at both the mRNA and protein levels in both cell types. The CP-MSCs and WJ-MSCs also had the capacities to differentiate into cells of mesodermal (adipogenic and osteogenic) and endodermal (hepatogenic) lineages. Expression of adipogenesis-related genes was higher in CP-MSCs than in WJ-MSCs, whereas WJ-MSCs accumulated more mineralized matrix than CP-MSCs. The WJ-MSCs expressed more of CYP3A4 mRNA, a marker for mature hepatocytes, than CP-MSCs. Thus, we propose that CP-MSCs and WJ-MSCs are useful sources of cells for appropriate clinical applications in the treatment of various degenerative diseases.
"Our finding was similar to Kim e al., results.16 They revealed that proliferative potential of WJ-MSCs tended to be higher than that of chorionic plate derived mesenchymal stem cells16. The MSCs from three sources were successfully cultured until passage 10-12 and beyond that, the cells underwent morphological changes, formation of vacuoles with elongated cytoplasmic process and eventually senesced. "
[Show abstract][Hide abstract] ABSTRACT: Objective: Mesenchymal stromal cells (MSCs) are considered as an excellent source in regenerative medicine, but availability and ethical problems limited their routine use. Therefore, another available source with easy procedure and exempt from ethical debate is important. The purpose of this study is to isolate and characterize the MSCs from human placenta. The stromal cells were isolated from Placental Decidua Basalis (PDB-MSC), Umbilical cord Wharton’s Jelly (WJ-MSC) and Amniotic Membrane (AM-MSC).
Methods: Full term human placentas (n=4), from cesarean section delivery were collected. Small fragments from different parts were cultures as explants. The immunophenotyping, mesodermal differentiation, growth kinetics and stemness gene expression was studied.
Results: The cultivated cells from three sources expressed CD44, CD105, and CD90. Gene expression of NANOG and OCT4 confirmed the undifferentiated state. The doubling-times for WJ-MSCs, PLC-MSCs and AM-MSCs, respectively, were 21±8h, 28±9h and 25±9h at passage three and 30±5h, 45±7h and 45±7h at passage tenth. The proliferative potential of WJ-MSCs tended to be higher than the other two sources.
Conclusion: The fetal derives stromal cells; especially the early passages of WJ-MSCs are available supplies for large scale production of MSC for using in clinical studies or research projects.
Pakistan Journal of Medical Sciences Online 09/2014; 30(5):1022-6. DOI:10.12669/pjms.305.4537 · 0.23 Impact Factor
"Furthermore, UC MSCs, in contrast to bone marrow MSCs, do not express tumor-associated fibroblast phenotypes and therefore have no opportunity to grow solid tumors . Moreover, UC MSCs have a higher rate of gene expression related to cell adhesion, morphogenesis, angiogenesis and neurogenesis than UC blood–derived MSCs do , and they can accumulate more mineralized matrix than placenta-derived MSCs , indicating that UC MSCs may be used as an optimal cell therapy option. "
[Show abstract][Hide abstract] ABSTRACT: Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have shown a good safety profile and therapeutic effect in severe and refractory systemic lupus erythematosus (SLE) in our single-center pilot study. The present multicenter clinical trial was undertaken to assess the safety and efficacy of allogenic UC MSC transplantation (MSCT) in active and refractory SLE patients.
Forty patients with active SLE were enrolled from 4 clinical centers in China. Allogenic UC MSCs were infused intravenously on days 0 and 7. Primary endpoints were safety profiles. Second endpoints included major clinical response (MCR), partial clinical response (PCR) and relapse. Clinical index including SLEDAI score, BILAG score, renal functional indices were also determined.
The overall survival rate was 92.5% (37/40). UC-MSCT was well tolerated, and no transplantation-related adverse event was observed. Thirteen and eleven patients achieved MCR (13/40, 32.5%) and PCR (11/40, 27.5%) during 12 months follow-up, respectively. Then three and four patients experienced disease relapse at 9 (12.5%) and 12 (16.7%) months follow-up, after a prior clinical response. SLEDAI score significantly decreased at 3, 6, 9 and 12 months follow-up. Total BILAG score markedly decreased at 3 months and continued to decrease at subsequent follow-up visits. BILAG scores for renal, hematopoietic and cutaneous systems significantly improved. For those with lupus nephritis, 24-hour proteinuria declined after transplantation, with statistical differences at 9 and 12 months. Serum creatinine and urea nitrogen decreased to the lowest level at 6 months, while these values slightly increased at 9 and 12 months as a result of 7 relapsed cases. In addition, serum levels of albumin and complement 3 increased after MSCT, peaked at 6 months and then slightly declined at 9 and 12 months follow-up. Serum antinuclear antibody and anti-double-strand DNA antibody decreased after MSCT, with statistical differences at 3 months follow-up.
UC-MSCT results in satisfactory clinical response in SLE patients. However, several cases experienced disease relapse after 6 months, indicating the necessity to repeat MSCT after 6 months.Registration number: NCT01741857.
"Umbilical cord mesenchymal stem cells (UC- MSCs) not only possess adult stem cell markers CD73, CD90, and CD105 for which a large consensus exists, but they also show a number of ESC properties; actually, they express human ESC markers such as Tra-1-60, Tra-1-81, SSEA-1 (stage-specific embryonic antigen-1), SSEA-4, alkaline phosphatase, and even markers from embryoid bodies in vitro (Carlin et al. 2006). Moreover, UC-MSCs at relatively lower levels, express the pluripotency markers Oct-4, Sox-2, and Nanog (La Rocca et al. 2009; Karahuseyinoglu et al. 2007; Kim et al. 2011). So, UC-MSCs possess higher multipotency than other MSCs such as bone marrow (BM) or fat-derived MSCs (Fong et al. 2011). "
[Show abstract][Hide abstract] ABSTRACT: Adult stem cells are of particular importance for applications in regenerative medicine. Umbilical cord was established recently as an alternative source of mesenchymal stem cell (MSC) instead of bone marrow (BM) and is superior to BM and other adult tissues according to several MSC properties. Additionally, for the purpose of cell therapy in clinical scale, steps of cell isolation, expansion and culture required to be precisely adjusted in order to obtain the most cost-effective, least time-consuming, and least labor-intensive method. Therefore, in this study, we are going to compare two simple and cost-effective explant culture methods for isolation of MSCs from human umbilical cord. One of the methods isolates cells from entire cord and the other from Wharton's jelly matrix. Isolated cells then cultured in simple medium without addition of any growth factor. MSCs obtained via both methods display proper and similar characteristics according to morphology, population doubling time, post-thaw survival, surface antigenicity and differentiation into adipocytes, osteocytes, and chondrocytes. MSCs can easily be obtained from the entire cord and Wharton's jelly, and it seems that both tissues are appropriate sources of stem cells for potential use in regenerative medicine. However, from technical largescale preview, MSC isolation from entire cord piece is less labor-intensive and time-consuming than from Wharton's jelly part of the cord.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.